Market Research Logo

Multiple Sclerosis  -Epidemiology Forecast to 2027

DelveInsight’s ‘Multiple Sclerosis - Epidemiology Forecast to 2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Multiple Sclerosis in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

Geography Covered
• The United States
• EU5 (Germany, France, Italy, Spain and the United Kingdom)
• Japan

Study Period: 2016-2027

Multiple Sclerosis Epidemiology
The Multiple Sclerosis (MS) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. The epidemiology data for Multiple Sclerosis are studied through all possible division to give a better understanding about the Disease scenario in 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Multiple Sclerosis Epidemiology Segmentation
The disease epidemiology covered in the report is segmented by Gender [male/female], age group [≤19 years, 20-29 years, 30-39 years, 40-49 years, 50-59 years, 60-69 years, 70-79 years, and ≥80 years], sub-types [Relapsing Remitting MS, Primary Progressive MS and Progressive relapsing MS] and Expanded disability status scale (EDSS) [0.0-1.5, 2.0-3.5, 4.0-5.5, 6.0-7.5 and 8.0-9.5], thus presenting overall detailed analysis of the patient pool characteristics.

The DelveInsight report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

According to DelveInsight, the prevalent population of Multiple Sclerosis was estimated to be 1.98 Million [7MM] in 2016 and, is expected to increase at a CAGR of XX% during the study period i.e., 2016-2027. United States accounts for the highest MS Cases, followed by EU5 (Germany, France, Italy, Spain & UK) and Japan. In United States, the peak prevalence has been observed in patients aged 45–49 years in both female and male participants.

Report Scope
• The report covers detailed overview of Multiple Sclerosis explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The report provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
• The Report assesses the disease risk and burden and highlights the unmet needs of Multiple Sclerosis
• The Report helps to recognize the growth opportunities in the 7MM with respect to the patient population
• The report provides the segmentation of the disease epidemiology by gender, age-group, sub-types and EDSS score in 7MM

Key strengths
• 10 Year Forecast of Multiple Sclerosis epidemiology
• 7MM Coverage
• Total Prevalent Cases of Multiple Sclerosis
• Prevalent Cases according to segmentation: Gender-specific prevalence, age-specific prevalence, sub-type specific prevalence and prevalence based upon EDSS score

Key assessments
• Patient Segmentation
• Disease Risk & Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population


1. Report Introduction
2. Multiple Sclerosis Epidemiology Overview at a Glance
2.1. Prevalent Population of Multiple Sclerosis in 2017
2.2. Prevalent Population of Multiple Sclerosis in 2027
3. Disease Background and Overview: Multiple Sclerosis (MS)
3.1. Introduction
3.2. Risk Factors
3.3. Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
3.7. Expanded Disability Status Scale (EDSS)
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. Prevalent Population of Multiple Sclerosis in 7MM
4.4. Prevalent Population of Multiple Sclerosis in 7MM – By Region
4.5. Prevalent Population of Multiple Sclerosis in 7MM – Distribution (2017)
4.6. Prevalent Population of Multiple Sclerosis in 7MM – Distribution (2027)
5. Epidemiology of Multiple Sclerosis
6. United States
6.1. Assumptions and Rationale
6.2. Prevalent Population of Multiple Sclerosis in United States
6.3. Sex-Specific Prevalence of Multiple Sclerosis in United States
6.4. Sub-type Specific Prevalence of Multiple Sclerosis in United States
6.5. Age-Specific Prevalence of Multiple Sclerosis in United States
6.6. Prevalence of Multiple Sclerosis based on EDSS Score in United States
7. Germany
7.1. Assumptions and Rationale
7.2. Prevalent Population of Multiple Sclerosis in Germany
7.3. Sex-Specific Prevalence of Multiple Sclerosis in Germany
7.4. Sub-type Specific Prevalence of Multiple Sclerosis in Germany
7.5. Age-Specific Prevalence of Multiple Sclerosis in Germany
7.6. Prevalence of Multiple Sclerosis based on EDSS Score in Germany
8. France
8.1. Assumptions and Rationale
8.2. Prevalent Population of Multiple Sclerosis in France
8.3. Sex-Specific Prevalence of Multiple Sclerosis in France
8.4. Sub-type Specific Prevalence of Multiple Sclerosis in France
8.5. Age-Specific Prevalence of Multiple Sclerosis in France
8.6. Prevalence of Multiple Sclerosis based on EDSS Score in France
9. Italy
9.1. Assumptions and Rationale
9.2. Prevalent Population of Multiple Sclerosis in Italy
9.3. Sex-Specific Prevalence of Multiple Sclerosis in Italy
9.4. Sub-type Specific Prevalence of Multiple Sclerosis in Italy
9.5. Age-Specific Prevalence of Multiple Sclerosis in Italy
9.6. Prevalence of Multiple Sclerosis based on EDSS Score in Italy
10. Spain
10.1. Assumptions and Rationale
10.2. Prevalent Population of Multiple Sclerosis in Spain
10.3. Sex-Specific Prevalence of Multiple Sclerosis in Spain
10.4. Sub-type Specific Prevalence of Multiple Sclerosis in Spain
10.5. Age-Specific Prevalence of Multiple Sclerosis in France
10.6. Prevalence of Multiple Sclerosis based on EDSS Score in Spain
11. United Kingdom
11.1. Assumptions and Rationale
11.2. Prevalent Population of Multiple Sclerosis in United Kingdom
11.3. Sex-Specific Prevalence of Multiple Sclerosis in United Kingdom
11.4. Sub-type Specific Prevalence of Multiple Sclerosis in United Kingdom
11.5. Age-Specific Prevalence of Multiple Sclerosis in United Kingdom
11.6. Prevalence of Multiple Sclerosis based on EDSS Score in United Kingdom
12. Japan
12.1. Assumptions and Rationale
12.2. Prevalent Population of Multiple Sclerosis in Japan
12.3. Sex-Specific Prevalence of Multiple Sclerosis in Japan
12.4. Sub-type Specific Prevalence of Multiple Sclerosis in Japan
12.5. Age-Specific Prevalence of Multiple Sclerosis in Japan
12.6. Prevalence of Multiple Sclerosis based on EDSS Score in Japan
13. Unmet Needs
14. Appendix
15. Report Methodology
15.1. Sources Used
16. Consulting Services
17. Disclaimer
18. About DelveInsight
List Of Tables
Table 1: Expanded Disability Status Scale (EDSS)
Table 2: Total Prevalent Population of Multiple Sclerosis in 7 MM (2016-2027)
Table 3: Prevalent Population of Multiple Sclerosis in 7MM- By Region (2016-2027)
Table 4: Prevalent Population of Multiple Sclerosis in United States (2016-2027)
Table 5: Sex-Specific Prevalent Population of Multiple Sclerosis in United States (2016-2027)
Table 6: Sub-type Specific Prevalent Population of Multiple Sclerosis in United States (2016-2027)
Table 7: Age Specific Prevalent Population of Multiple Sclerosis in United States (2016-2027)
Table 8: Prevalent Population of Multiple Sclerosis based on EDSS Score in United States (2016-2027)
Table 9: Prevalent Population of Multiple Sclerosis in Germany (2016-2027)
Table 10: Sex-Specific Prevalent Population of Multiple Sclerosis in Germany (2016-2027)
Table 11: Sub-type Specific Prevalent Population of Multiple Sclerosis in Germany (2016-2027)
Table 12: Age Specific Prevalent Population of Multiple Sclerosis in Germany (2016-2027)
Table 13: Prevalent Population of Multiple Sclerosis based on EDSS Score in Germany (2016-2027)
Table 14: Prevalent Population of Multiple Sclerosis in France (2016-2027)
Table 15: Sex-Specific Prevalent Population of Multiple Sclerosis in France (2016-2027)
Table 16: Sub-type Specific Prevalent Population of Multiple Sclerosis in France (2016-2027)
Table 17: Age Specific Prevalent Population of Multiple Sclerosis in France (2016-2027)
Table 18: Prevalent Population of Multiple Sclerosis based on EDSS Score in France (2016-2027)
Table 19: Prevalent Population of Multiple Sclerosis in Italy (2016-2027)
Table 20: Sex-Specific Prevalent Population of Multiple Sclerosis in Italy (2016-2027)
Table 21: Sub-type Specific Prevalent Population of Multiple Sclerosis in Italy (2016-2027)
Table 22: Age Specific Prevalent Population of Multiple Sclerosis in Italy (2016-2027)
Table 23: Prevalent Population of Multiple Sclerosis based on EDSS Score in Italy (2016-2027)
Table 24: Prevalent Population of Multiple Sclerosis in Spain (2016-2027)
Table 25: Sex-Specific Prevalent Population of Multiple Sclerosis in Spain (2016-2027)
Table 26: Sub-type Specific Prevalent Population of Multiple Sclerosis in Spain (2016-2027)
Table 27: Age Specific Prevalent Population of Multiple Sclerosis in Spain (2016-2027)
Table 28: Prevalent Population of Multiple Sclerosis based on EDSS Score in Spain (2016-2027)
Table 29: Prevalent Population of Multiple Sclerosis in United Kingdom (2016-2027)
Table 30: Prevalent Population of Multiple Sclerosis in United Kingdom (2016-2027)
Table 31: Sub-type Specific Prevalent Population of Multiple Sclerosis in United Kingdom (2016-2027)
Table 32: Age Specific Prevalent Population of Multiple Sclerosis in United Kingdom (2016-2027)
Table 33: Prevalent Population of Multiple Sclerosis based on EDSS Score in United Kingdom (2016-2027)
Table 34: Prevalent Population of Multiple Sclerosis in Japan (2016-2027)
Table 35: Sex-Specific Prevalent Population of Multiple Sclerosis in Japan (2016-2027)
Table 36: Sub-type Specific Prevalent Population of Multiple Sclerosis in Japan(2016-2027)
Table 37: Age Specific Prevalent Population of Multiple Sclerosis in Japan (2016-2027)
Table 38: Prevalent Population of Multiple Sclerosis based on EDSS Score in Japan (2016-2027)
List Of Figures
Figure 1: Types of MS 14
Figure 2: Risk factors associated with MS 16
Figure 3: The immunological complexity of the immune/cytokine network in multiple sclerosis 21
Figure 4: Total Prevalent Population of Multiple Sclerosis in 7 MM (2016-2027) 33
Figure 5: Prevalent Population of Multiple Sclerosis in 7MM- By Region(2016-2027) 34
Figure 6: Prevalent Population of Multiple Sclerosis in United States (2016-2027) 39
Figure 7: Sex- Specific Prevalent Population of Multiple Sclerosis in United States (2016-2027) 40
Figure 8: Sub-type Specific Prevalent Population of Multiple Sclerosis in United States (2016-2027) 41
Figure 9: Age Specific Prevalent Population of Multiple Sclerosis in United States (2016-2027) 42
Figure 10: Prevalent Population of Multiple Sclerosis based on EDSS Score in US (2016-2027) 43
Figure 11: Prevalent Population of Multiple Sclerosis in Germany (2016-2027) 46
Figure 12: Sex- Specific Prevalent Population of Multiple Sclerosis in Germany (2016-2027) 47
Figure 13: Sub-type Specific Prevalent Population of Multiple Sclerosis in Germany (2016-2027) 48
Figure 14: Age Specific Prevalent Population of Multiple Sclerosis in Germany (2016-2027) 49
Figure 15: Prevalent Population of Multiple Sclerosis based on EDSS Score in Germany (2016-2027) 50
Figure 16: Prevalent Population of Multiple Sclerosis in France (2016-2027) 53
Figure 17: Sex- Specific Prevalent Population of Multiple Sclerosis in France (2016-2027) 54
Figure 18: Sub-type Specific Prevalent Population of Multiple Sclerosis in France (2016-2027) 55
Figure 19: Age Specific Prevalent Population of Multiple Sclerosis in France (2016-2027) 56
Figure 20: Prevalent Population of Multiple Sclerosis based on EDSS Score in France (2016-2027) 57
Figure 21: Prevalent Population of Multiple Sclerosis in Italy (2016-2027) 60
Figure 22: Sex- Specific Prevalent Population of Multiple Sclerosis in Italy (2016-2027) 61
Figure 23: Sub-type Specific Prevalent Population of Multiple Sclerosis in Italy (2016-2027) 62
Figure 24: Age Specific Prevalent Population of Multiple Sclerosis in Italy (2016-2027) 63
Figure 25: Prevalent Population of Multiple Sclerosis based on EDSS Score in Italy (2016-2027) 64
Figure 26: Prevalent Population of Multiple Sclerosis in Spain (2016-2027) 67
Figure 27: Sex- Specific Prevalent Population of Multiple Sclerosis in Spain (2016-2027) 68
Figure 28: Sub-type Specific Prevalent Population of Multiple Sclerosis in Spain (2016-2027) 69
Figure 29: Age Specific Prevalent Population of Multiple Sclerosis in Spain (2016-2027) 70
Figure 30: Prevalent Population of Multiple Sclerosis based on EDSS Score in Spain (2016-2027) 71
Figure 31: Prevalent Population of Multiple Sclerosis in United Kingdom (2016-2027) 74
Figure 32: Sex- Specific Prevalent Population of Multiple Sclerosis in United Kingdom (2016-2027) 75
Figure 33: Sub-type Specific Prevalent Population of Multiple Sclerosis in United Kingdom (2016-2027) 76
Figure 34: Age Specific Prevalent Population of Multiple Sclerosis in United Kingdom (2016-2027) 77
Figure 35: Prevalent Population of Multiple Sclerosis based on EDSS Score in UK (2016-2027) 78
Figure 36: Prevalent Population of Multiple Sclerosis in Japan (2016-2027) 81
Figure 37: Sex- Specific Prevalent Population of Multiple Sclerosis in Japan (2016-2027) 82
Figure 38: Sub-type Specific Prevalent Population of Multiple Sclerosis in Japan (2016-2027) 83
Figure 39: Age Specific Prevalent Population of Multiple Sclerosis in Japan (2016-2027) 84
Figure 40: Prevalent Population of Multiple Sclerosis based on EDSS Score in Japan (2016-2027) 85

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report